ERBB3 and cancer: In addition, we found that HER2 phosphorylation was sensitive to lapatinib but not PHA in Snu5, Okajima, KatoII and OE33 cells, indicating that the Met–HER3 signaling axis is independent from HER2 activity in these MET-amplified cancer cells.